MeSH D018358 - neuroendocrine tumors
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D017599:Neuroectodermal tumors
0 Companies
0 Drugs
Success rate
D018358:Â
Neuroendocrine tumors
D000237:Basophil adenoma
0 Companies
0 Drugs
Success rate
D000238:Chromophobe adenoma
0 Companies
0 Drugs
Success rate
D000239:Acidophil adenoma
0 Companies
0 Drugs
Success rate
D001079:Apudoma
0 Companies
0 Drugs
Success rate
D002276:Carcinoid tumor
D008545:Melanoma
D009442:Neurilemmoma
0 Companies
0 Drugs
Success rate
D010235:Paraganglioma
0 Companies
0 Drugs
Success rate
D018278:Neuroendocrine carcinoma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Sunitinib | Sunitinib Accord |  | 2021-02-11 |  |  |
| Advanced Accelerator Applications | Lutetium (177lu) oxodotreotide, Lutetium lu 177 dotatate | Lutathera |  | 2017-09-26 |  |  |
| Edotreotide | SomaKit TOC |  | 2016-12-08 |  |  | |
| Cipla | Lanreotide | Lanreotide |  | 2021-12-17 |  |  |
| CP Pharmaceuticals International CV | Sunitinib | Sutent |  | 2006-01-26 |  |  |
| Dr Reddys Laboratories | Sunitinib | Sunitinib |  | 2022-04-11 |  |  |
| Eugia Pharma Specialties | Sunitinib | Sunitinib |  | 2024-03-14 |  |  |
| Ipsen | Lanreotide | Somatuline Depot |  | 2007-08-30 |  |  |
| Merck & Co | Avelumab | Bavencio |  | 2017-09-18 |  |  |
| Mylan | Sunitinib | Sunitinib |  | 2021-12-06 |  |  |
| NATCO Pharma | Sunitinib | Sunitinib |  | 2023-10-24 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
74%40/54
Phase 2
34%30/89
Phase 3
25%9/36
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use